Onkologie. 2014:8(1):15-18

Diagnosis and staging of prostate cancer

David Hradil, Vladimír Študent jr., Milan Král, Vladimír Študent
Urologická klinika LF UP a FN, Olomouc

Prostate cancer (PC) is the most common solid neoplasm in Europe and USA with the third highest mortality. Introduction of PSA – based

sreeening multiplied incidence with stagnant level of mortality. These results can be explained by shift to lower stage at the time of

diagnosis and also by improved therapeutic options.

Keywords: prostate cancer, diagnosis, PSA, staging

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradil D, Študent V, Král M, Študent V. Diagnosis and staging of prostate cancer. Onkologie. 2014;8(1):15-18.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Gelnarová J, Cancer incidence and mortality in the Czech Republic, Klin.Onkol 2010; 23: 311-324.
    2. Breza J, Bolješíková E, Kliment J. Liečba lokalizovaného karcinómu prostaty. In, Kliment J, Horňák M, Karcinom prostaty, Martin, Osveta, 1999: 15-193.
    3. Richie JP, Catalona WJ, Ahmann FR, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42(4): 365-374. Go to original source... Go to PubMed...
    4. Carvalhal GF, Smith DS, Mager DE, et al.Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999; 161: 835-839. Go to original source... Go to PubMed...
    5. Okotie OT, Roehl KA, Han M, et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007; 70(6): 1117-1120. Go to original source... Go to PubMed...
    6. Gossselaar C, Roobol MJ, Roemeling S, et al. The role of the Digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008; 54(3): 581-538. Go to original source... Go to PubMed...
    7. Lilja H, Christensson A, Dahlen U, et al. Prostate specific antigen in human Serum occurs predominantly in komplex with 1-antichymotrypsin, Clin Cem, 1999; 37: 1618-1625. Go to original source...
    8. Vessela RL, Lange PH. Issues in the assessment of prostate - specific antigen Immunoassays. An update. Urol.Clin.North. Am. 1997; 24: 261-268. Go to original source... Go to PubMed...
    9. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoprative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy, J. Urol. 1988; 139: 766-772. Go to original source... Go to PubMed...
    10. Semjonow A, Hamm M, Rathert P. Halflife of prostate-specific antigen after radical prostatectomy, Eur. Urol. 1992; 21: 200-205. Go to original source... Go to PubMed...
    11. Semjonow A, Roth S, Hamm M, Rather P. Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass, J. Urol., 1996; 155: 295-296. Go to original source... Go to PubMed...
    12. Oesterling JE, Rice DC, Glenski WJ, Berstralh EJ. Effects of cystoskopy, prostate biopsy and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993; 42: 276-282. Go to original source... Go to PubMed...
    13. Wojno KJ, Apoorva RV, Vessella RL, et al. Determination of the, ,Reflex range" and appropriate cutpoints for percent free PSA in 413 men reffered for prostatic evaluation using AxSYM systém.In: Advances in urology.Prostate Controversies: Diagnosis and Management. Detroit, 1996.
    14. Deliveliotis C, Alivizatos G, Stavropoulos NJ, et al. Influence of digital rectal examination, cystoskopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen, Urol. Int. 1994; 53: 186-190. Go to original source... Go to PubMed...
    15. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 1995; 274: 1214-1220. Go to original source...
    16. Smith DS, Catalona WJ, Keetch DW. Comparison of percent free PSA and PSA density as method to enhance the specificity of PSA screening. J. Urol. 1996; 155: 422A.
    17. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for thein concentrations and ratios. J. Urol, 1995; 15: 1090-1095. Go to original source...
    18. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristics curves. J. Urol. 1994; 152: 2031-2036. Go to original source... Go to PubMed...
    19. Cookson MS, Floyd MK, Ball TP, et al. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patiens with normal rectal examinations and intermediate prostate specific antigen levels. J. Urol. 1995; 154: 1070-1073. Go to original source... Go to PubMed...
    20. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patiens after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J. Urol, 1997; 158: 1441-1445. Go to original source... Go to PubMed...
    21. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and signifikance of detecable levels of serum prostate specific antigen after radical prostatectomy, J. Urol. 1994; 152: 1821-1825. Go to original source... Go to PubMed...
    22. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 1999; 281: 1591-1597. Go to original source... Go to PubMed...
    23. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseases, JAMA 1992; 267: 2215-2220. Go to original source...
    24. Student V, Grepl M, Král M. Má vyšetření PSA stále význam při vyhledávání karcinomu prostaty, Urolog.pro Praxi, 2006; 5: 214-218.
    25. Student V, Grepl M, Král M. PSA a včasná detekce karcinomu prostaty, Urol List, 2006; 4(4).
    26. Student V, Fiala R. První výsledky studie KAPROS v Olomouckém kraji, Čes Urol., 2006; 1: 19-22.
    27. Luboldt HJ, Schindletr JF, Rübben H. Age - Specific Reference Ranges for Prostate - Specific Antigen as a Marker for Prostate Cancer, Eur Urol, 2007; 5: 38-48. Go to original source...
    28. Belej K, a kol. Molekulární genetika a prostate cancer gene 3 (PCA3) v diagnostice karcinomu prostaty. Urolog pro Praxi, 2010; 11(2): 82-85.
    29. Heidenreich A, Aus C, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2013: 17-19.
    30. Belej K, a kol. Transrektální biopsie v diagnostice karcinomu prostaty, Urolog. pro Praxi, 2009; 10(5)
    31. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.4.2013. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed September 5, 2013.
    32. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9): 1228-1242. Review. PubMed PMID: 16096414. Go to original source... Go to PubMed...
    33. Tempany C, Franco F, Prostate MRI. Update and current roles. Applied Radiology 2012; 41(3): 17-22. Go to original source...
    34. Dickinson L, Ahmed HU, Allen C, Berentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkhan A, Padhani AR, Persar R, Puech P, Punwanni S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M. Magnetic resonance paging for the detection, localization, and characterisation of prostate cancer: recomendations from a European konsensus meeting. Eur Urol. 2011; 59(4): 477-494. Go to original source... Go to PubMed...
    35. Barta J, Ryznarova Z, Klezl P, Zatura F, Adamova M, Kašpar M, Novák J. Postavení magnetické rezonance a magnetické rezonanční spektroskopie v diagnostice karcinomu prostaty. Ces Urol 2010; 14(3): 186-196.
    36. Mocikova I, Babela J, Balaz V. Prostate cancer - the role of magnetic resonance imaging. Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 156(2): 103-171. Go to original source... Go to PubMed...
    37. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA, 1998; 280: 969-974. Go to original source... Go to PubMed...
    38. Král M, Študent V, Hrabec M. Predikční nomogramy u karcinomu prostaty. Urolog. pro Praxi, 2008; 9(1): 33-36.
    39. Briganti A, Joniau S, Gontero P, et al. Identifying the Best Candidate for Radical Prostatectomy Among with High-Risk Prostate Cancer, Eur Urol, 2012; 61(3): 584-592. Go to original source... Go to PubMed...
    40. Beheshti M, Vali R, Langsteger W. [18F] Fluorocholine PET/ CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34(8): 1316-1317. Go to original source... Go to PubMed...
    41. Dickinson L, Hashim U. Ahmed, Allen C, et al. Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting, Eur Urol, 2011; 59(4): 477-494. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.